Literature DB >> 16942596

Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes.

Hélène Castel1, Mickaël Diallo, David Chatenet, Jérôme Leprince, Laurence Desrues, Marie-Thérèse Schouft, Marc Fontaine, Christophe Dubessy, Isabelle Lihrmann, Elisabeth Scalbert, Maria Malagon, Hubert Vaudry, Marie-Christine Tonon, Pierrick Gandolfo.   

Abstract

The urotensin II (UII) gene is primarily expressed in the central nervous system, but the functions of UII in the brain remain elusive. Here, we show that cultured rat astrocytes constitutively express the UII receptor (UT). Saturation and competition experiments performed with iodinated rat UII ([(125)I]rUII) revealed the presence of high- and low-affinity binding sites on astrocytes. Human UII (hUII) and the two highly active agonists hUII(4-11) and [3-iodo-Tyr9]hUII(4-11) were also very potent in displacing [(125)I]rUII from its binding sites, whereas the non-cyclic analogue [Ser5,10]hUII(4-11) and somatostatin-14 could only displace [(125)I]rUII binding at micromolar concentrations. Reciprocally, rUII failed to compete with [(125)I-Tyr0,D-Trp8]somatostatin-14 binding on astrocytes. Exposure of cultured astrocytes to rUII stimulated [(3)H]inositol incorporation and increased intracellular Ca(2+) concentration in a dose-dependent manner. The stimulatory effect of rUII on polyphosphoinositide turnover was abolished by the phospholipase C inhibitor U73122, but only reduced by 56% by pertussis toxin. The GTP analogue Gpp(NH)p caused its own biphasic displacement of [(125)I]rUII binding and provoked an affinity shift of the competition curve of rUII. Pertussis toxin shifted the competition curve towards a single lower affinity state. Taken together, these data demonstrate that rat astrocytes express high- and low-affinity UII binding sites coupled to G proteins, the high-affinity receptor exhibiting the same pharmacological and functional characteristics as UT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16942596     DOI: 10.1111/j.1471-4159.2006.04130.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

Review 1.  A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-27       Impact factor: 3.000

2.  Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.

Authors:  D Chatenet; M Létourneau; Q T Nguyen; N D Doan; J Dupuis; A Fournier
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

3.  Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart.

Authors:  N D Doan; T T M Nguyen; M Létourneau; K Turcotte; A Fournier; D Chatenet
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Cadmium-induced genome-wide DNA methylation changes in growth and oxidative metabolism in Drosophila melanogaster.

Authors:  De-Long Guan; Rui-Rui Ding; Xiao-Yu Hu; Xing-Ran Yang; Sheng-Quan Xu; Wei Gu; Min Zhang
Journal:  BMC Genomics       Date:  2019-05-09       Impact factor: 3.969

5.  Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.

Authors:  C Lecointre; L Desrues; J E Joubert; N Perzo; P-O Guichet; V Le Joncour; C Brulé; M Chabbert; R Leduc; L Prézeau; A Laquerrière; F Proust; P Gandolfo; F Morin; H Castel
Journal:  Oncogene       Date:  2015-01-19       Impact factor: 9.867

6.  Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.

Authors:  Marie Jarry; Céline Lecointre; Céline Malleval; Laurence Desrues; Marie-Thérèse Schouft; Vadim Lejoncour; François Liger; Gildas Lyvinec; Benoît Joseph; Nadège Loaëc; Laurent Meijer; Jérôme Honnorat; Pierrick Gandolfo; Hélène Castel
Journal:  Neuro Oncol       Date:  2014-06-02       Impact factor: 12.300

7.  State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells.

Authors:  Eugen Brailoiu; Xiaohua Jiang; G Cristina Brailoiu; Jun Yang; Jaw Kang Chang; Hong Wang; Nae J Dun
Journal:  Peptides       Date:  2008-01-31       Impact factor: 3.750

8.  Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Authors:  David Chatenet; Thi-Tuyet M Nguyen; Myriam Létourneau; Alain Fournier
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-02       Impact factor: 5.555

9.  The octadecaneuropeptide ODN protects astrocytes against hydrogen peroxide-induced apoptosis via a PKA/MAPK-dependent mechanism.

Authors:  Yosra Hamdi; Hadhemi Kaddour; David Vaudry; Seyma Bahdoudi; Salma Douiri; Jérôme Leprince; Helene Castel; Hubert Vaudry; Marie-Christine Tonon; Mohamed Amri; Olfa Masmoudi-Kouki
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

10.  The stimulatory effect of the octadecaneuropeptide ODN on astroglial antioxidant enzyme systems is mediated through a GPCR.

Authors:  Yosra Hamdi; Hadhemi Kaddour; David Vaudry; Salma Douiri; Seyma Bahdoudi; Jérôme Leprince; Hélène Castel; Hubert Vaudry; Mohamed Amri; Marie-Christine Tonon; Olfa Masmoudi-Kouki
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.